NCT07920939
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in HbA1c from baseline to week 26 (non-inferiority test)
Timeframe: baseline to week 26
Secondary (9)
Percentage of time in range (TIR) between 3.9-10.0 mmol/L (inclusive) during weeks 23 to 26, assessed by continuous glucose monitoring system (CGMS)
Change in HbA1c from baseline to week 26 (superiority test)
Change in HbA1c from baseline to week 52
Percentage of participants at week 26 and 52 achieving HbA1c <7%
Percentage of participants at week 26 and 52 achieving HbA1c <7% without level 2-3 hypoglycemia;
Show 4 moreShow less
Change in fasting plasma glucose (FPG) from baseline to week 26 and 52
Change in pre-breakfast self-monitored blood glucose (SMBG) from baseline to week 26 and 52
Percentage of time in range (TIR) of 3.9-10.0 mmol/L (inclusive) measured by CGMS during weeks 49-52
Incidence and event rate of hypoglycemia from baseline to week 26 and 52
Arms and interventions
Treatment group AExperimental
SHR-3167 Injection
Treatment group BActive comparator
Insulin glargine (IGlar)
Drugs: SHR-3167 Injection, Insulin glargine (IGlar)
Sites
2 sites in 1 country